Cryptophycin-induced hyperphosphorylation of Bcl-2, cell cycle arrest and growth inhibition in human H460 NSCLC cells

Cancer Chemotherapy and Pharmacology

Volumn 47, Issue 2, 2001, Pages 170-178

  Lu, K ^a   Dempsey, J ^a   Schultz, R M ^a   Shih, C ^a   Teicher, B A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Bcl 2; Cell cycle arrest; Cryptophycins; Microtubule inhibitors

Indexed keywords

CRYPTOPHYCIN 52; CRYPTOPHYCIN 55; CRYPTOPHYCIN DERIVATIVE; PACLITAXEL; PROTEIN BCL 2; UNCLASSIFIED DRUG; VINBLASTINE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL HETEROGENEITY; CELL PROTECTION; CONTROLLED STUDY; DEPOLYMERIZATION; DOSE TIME EFFECT RELATION; DRUG POTENCY; HUMAN; HUMAN CELL; LETHALITY; LUNG NON SMALL CELL CANCER; MICROTUBULE ASSEMBLY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; CELL SURVIVAL; DEPSIPEPTIDES; G2 PHASE; HUMANS; LUNG NEOPLASMS; MITOSIS; PEPTIDES, CYCLIC; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 0034913052     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000210     Document Type: Article

References (42)

1. The effect of microtubule agents on signal transduction pathways of apoptosis: A review
2. Prevention of apoptosis as a mechanism of drug resistance
3. Regulation of Bcl2 phosphorylation by stress response kinase pathway
4. Potent antitumor proteasome inhibitors: A novel trigger for Bcl2 phosphorylation to induce apoptosis
5. Bcl-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy
6. Phosphorylation of Bcl-2 after exposure of human leukemic cells to retinoic acid
7. Bcl-2 and apoptosis in lymph node positive breast carcinoma
8. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma
9. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway
10. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells
11. Raf-1/bcl-2 phosphorylation: A step from microtubule damage to cell death
12. Taxol can induce phosphorylation of bcl-2 in multiple myeloma cells and potentiate dexamethasone-induced apoptosis
13. Mitotic phosphorylation of bcl-2 during normal cell cycle progression and Taxol-induced growth arrest
14. Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: Association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest
15. Taxol-induced bcl-2 phosphorylation in ovarian cancer cell monolayer and spheroids
16. Possible mechanisms of paclitaxel-induced apoptosis
17. Deletion of the loop of Bcl-2 completely blocks paclitaxel-induced apoptosis
18. Pharmaceuticals from cultured algae
19. Preclinical anti-cancer activity of cryptophycin-8
20. Mechanism of action of the unusually potent microtubule inhibitor, cryptophycin 1
21. Preclinical antitumor activity of cryptophycin-52/55 (C-52; C-55) against human tumors in SCID mice
22. LY355702 and LY355703, new cryptophycin analogues with antitumor activity against human tumor xenograft
23. Total structures of cryptophycins, potent antitumor desipeptides from the blue-green algae Nostoc sp. Strain GSV
24. Mechanism of action of cryptophycin
25. Cryptophycin: A new microtubule agent active against drug-resistant cells
26. Pharmacological probes of microtubule function
27. Microtubule dynamics: Taking aim at a moving target
28. Antimitotic natural products and their interactions with tubulin
29. Characterization of the interaction of cryptophycin 1 with tubulin: Binding in the vinca domain, competitive inhibition of dolastatin 10 binding, and an unusual aggregation reaction
30. Interaction of cryptophycin 1 with tubulin and microtubules
31. Induction of apoptosis by cryptophycin 1, a new antimicrotubule agent
32. Cryptophycin 1 binds to tubulin at a site distinct from the colchicine binding site and at a site that may overlap the vinca binding site
33. Phase I trial of the cryptophycin analogue LY355703 administered as an IV infusion, D1 and D8, repeated every 21 days
34. Binding of the epoxide cryptophycin analog, LY355703 to a bumin and its effects on in vitro antiproliferative activity
35. In vitro pharmacology of LY355703 (cryptophycin 52) in human tumor cell lines
36. L-dopa decarboxylase activity (DDC): A distinguishing biomarker for the growth of small cell lung cancer (SCCL) in tissue culture
37. Effects of dibutyryl cyclic adenosine 3′, 5′-monophosphate on the growth of cultured human small cell lung carcinoma and the specific cellular activity of L-dopa decarboxylase
38. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo
39. Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis
40. Bcl-2 inhibits early apoptotic events and reveals post-mitotic multinucleation without affecting cell cycle arrest in human epithelial tumor cells exposed to etoposide
41. Bcl-2 expression correlates with apoptosis induction but not tumor growth delay in transplantable murine lymphomas treated with different chemotherapy drugs